Skip to main content
Top
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Poster presentation

Effects of hypoxia on protein and gene expression in fibroblast-like synoviocytes

Authors: H El-Gabalawy, K Dasuri, C Hitchon, K Wong, G Ma, M Koshiji, S Der, O Wilkins, E Huang, J Wilkins

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

The synovial microenvironment in rheumatoid arthritis (RA) is often hypoxic with evidence of anaerobic metabolism. This results from an imbalance between high metabolic demands and impaired tissue perfusion due to microvascular damage. Cellular responses to hypoxia are mediated by the transcription factor HIF-1α, which is exquisitely and rapidly controlled by cellular oxygen tension. HIF-1α has been shown to play a key role in promoting tumor angiogenesis, and was recently shown to be critically important in inflammatory responses. …
Metadata
Title
Effects of hypoxia on protein and gene expression in fibroblast-like synoviocytes
Authors
H El-Gabalawy
K Dasuri
C Hitchon
K Wong
G Ma
M Koshiji
S Der
O Wilkins
E Huang
J Wilkins
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1432

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine